Phaseline

Companies › Amal Therapeutics

Amal Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATP128
Self-adjuvanted chimeric recombinant protein vaccine targeting GP128 antigen
GP128Phase 1Colorectal Cancer–
BI 754091
PD-1 inhibitor
PDCD1Phase 1Colorectal Cancer–
VSV-GP128
Recombinant VSV expressing LCMV GP antigen for prime-boost vaccination
–Phase 1Colorectal Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04046445ATP128Phase 1Colorectal CancerOncologyMay 2025
NCT04046445BI 754091Phase 1Colorectal CancerOncologyMay 2025
NCT04046445VSV-GP128Phase 1Colorectal CancerOncologyMay 2025

Targets

GP128 (1) PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.